SynthesisBMC ophthalmology2026
Efficacy of 0.01% low-dose atropine therapy for the myopia and premyopia in children: a meta-analysis and systematic review.
Synthesis in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimThe aim is to systematically analyze the efficacy of 0.01%low-dose atropine therapy for myopia control and prevention in children.
methodsAll the data were searched from the PubMed, Web of Science, Embase, CNKI and Cochrane Library. The Cochrane Handbook was used to evaluate the quality of the included studies. This meta- analysis was performed with the Revman 5.4 software.
resultsFifteen randomized controlled trials (RCTs) were included in this study with a total of 2527 patients, 1328 in treatment group and 1199 in control group. At a 12 month follow-up, compared with control group, low-dose atropine treatment could reduce the progression in spherical equivalent refractive (SER) for myopia and premyopia children (MD, 0.20; 95%CI,0.13 to 0.27; p < 0.05). Also, less change in axial length (AL) was shown in low-dose atropine group for both myopia and premyopia children (MD, -0.07; 95%CI, -0.09 to -0.06; p < 0.05). At a 24 month follow-up, compared with control group, low-dose atropine treatment could reduce the progression in SER for myopia and premyopia children (MD, 0.31; 95%CI, 0.06 to 0.55; p < 0.05). Less change in AL was shown in low-dose atropine group for myopia children (MD, -0.08; 95%CI, -0.13 to -0.02, p < 0.05) but no significant difference in the premyopia chidren.
conclusionThis meta-analysis shows that 0.01% low-dose atropine therapy could control the refraction progression of myopia children compared with the control group. There was no significant difference between 0.01% atropine and placebo on myopia prevention in the premyopia chidren.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.